|Mr. Werner Baumann||Chairman of Management & CEO||N/A||N/A||1962|
|Mr. Wolfgang U. Nickl||CFO & Member of Management Board||N/A||N/A||1969|
|Mr. Liam Condon||Member of Management Board||N/A||N/A||1968|
|Mr. Heiko W. J. Schipper||Head of Consumer Health Division & Member of Management Board||N/A||N/A||1969|
|Mr. Stefan Oelrich||Pres of Pharmaceuticals Division & Member of the Board of Management||N/A||N/A||1968|
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, and self-care solutions in the dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. Bayer Aktiengesellschaft has a collaboration agreement with MD Anderson Cancer Center at the University of Texas to develop cancer treatments; and research collaboration agreements with Haplogen GmbH and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. The company distributes its products through wholesalers, pharmacies, supermarket and drugstore chains, online and other retailers, and hospitals, as well as directly to farmers. It has strategic research alliance with Kyoto University, Sensyne Health plc, and Atomwise Inc.; and a collaboration agreement with OrigiMed (Shanghai) Co., Ltd. for the development and commercialization of companion diagnostics-in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
Bayer Aktiengesellschaft’s ISS Governance QualityScore as of December 6, 2019 is 4. The pillar scores are Audit: 10; Board: 3; Shareholder Rights: 1; Compensation: 3.